Open Innovation in Life Sciences 2025

23 Oct 2025 | Zurich, Switzerland

Register
Register
Register

Ralph Schiess

Founding CEO

Zurich Hub for Drug and Device Development (ZH3D)

Zurich, Switzerland

9 profile visitsSpeakerInvited Speaker

My organisation

At the Zurich Hub for Drug and Device Development (ZH3D), we are dedicated to driving innovation in the biopharmaceutical and medical device sectors. Our collaborative platform fosters partnerships between academia, industry, and healthcare professionals to accelerate the development of new treatments and technologies. We provide state-of-the-art facilities and expertise, enabling our members to navigate the complexities of drug and device development efficiently. Together, we are shaping the future of healthcare by enhancing the pipeline of life-saving therapies and solutions.
Read more

About me

Ralph Schiess worked for more than a decade in world-class academic institutions both in the US and Europe and gained over 10 years of experience in the diagnostic industry successfully developing products from scientific prototypes to commercial products. He is currently the founding CEO of ZH3D (Zurich Hub for Drug and Device Development) at the University of Zurich. He was CEO and co-founder of Proteomedix AG, a Swiss healthcare company with the mission to transform prostate cancer diagnosis, which was acquired by Onconetix in December 2023. Under his guidance, Proteomedix identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. He received his M.S. from the University of Zurich, followed by an internship at the Institute of System Biology in Seattle. Thereafter, he received a doctorate in Science from the Swiss Federal Institute of Technology.

Social media

Speaker sessions (1)

Thursday, 23 October 2025

09:15 - 09:45

Keynote 1: Navigating Ethical Challenges in Open Science from Discovery to Market

Track:Scientific Session
  • Open Innovation
  • Regulatory
  • Translational Science

This keynote examines the ethical dimensions of open science, from discovery to application, highlighting challenges around transparency, equity, and accountability in responsible innovation.